Cargando…
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747861/ https://www.ncbi.nlm.nih.gov/pubmed/31555463 http://dx.doi.org/10.1177/2055217319875471 |